CheckMate -648 marks the third global trial in which Opdivo demonstrated a significant benefit for patients with upper gastrointestinal cancers Data to be featured in an oral presentation during the ...

Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...

Opdivo is the first and only PD-1/L1 inhibitor to demonstrate superior first-line efficacy in upper GI cancers across histologies and tumor locations Statistically significant overall survival benefit ...

Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...

Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of ...

Opdivo plus chemotherapy or Yervoy demonstrated overall survival benefit in PD-L1-positive and all-randomised populations Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside ...

Immunotherapy-containing combinations significantly improved survival in advanced esophageal cancer as compared with standard chemotherapy, a large randomized trial showed. Median overall survival (OS ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy ...

+ indicates a censored value. NR, not reached; wk, weeks. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as first-line treatments for adults with unresectable advanced or metastatic ...